Buscar
01/02/2023
BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis
Fusta-Novell, X, Garcia-Herrera, A, Yelamos, O. BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2021.10.022. PMID:36216154. IF:(Q/D).
01/01/2023
Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives
Camina-Conforto, G, Mateu-Arrom L., López-Ferrer A., Puig L.. Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives. Patient Preference and Adherence. 2023; 17DOI:10.2147/PPA.S350760. PMID:37408843. IF:2.000(Q2/4D).
01/01/2023
Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain
Artime E., Serra E., Mert C., Díaz-Cerezo S., Huete T., Hernández-Subirá I., Lledo-Bryant L., Sicras-Mainar A.. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain. Actas Dermo-Sifiliograficas. 2023; 114(1)DOI:10.1016/j.ad.2022.08.025. PMID:36368579. IF:(Q/D).
01/01/2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober B., Paul C., Blauvelt A., Thaçi D., Puig L., Lebwohl M., White K., Vanvoorden V., Deherder D., Gomez N.N., Eyerich K.. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(3)DOI:10.1016/j.jaad.2023.04.063. PMID:37182701. IF:12.800(Q1/1D).